NCT00632502

Neutrophilic Asthma Study With Navarixin (MK-7123, SCH 527123) (MK-7123-017)(COMPLETED)

Safety of SCH 527123 in Subjects With Neutrophilic Asthma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 37 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

4-Week Safety Study in Subjects with Neutrophilic Asthma

Detailed description

Effect of treatment with navarixin (MK-7123, SCH 527123) on sputum neutrophils and asthma symptoms

Conditions

• Neutrophilic Asthma

Interventions

Type	Name	Description
DRUG	Navarixin	Navarixin 30 mg capsule to be taken by mouth once daily in the morning for 4 weeks.
DRUG	Placebo	Placebo capsule to match navarixin to be taken by mouth once daily in the morning for 4 weeks.
DRUG	Rescue medication	Participant choice of short-acting beta-2 agonist (salbutamol/albuterol), anticholinergic, or combination medication as needed for asthma symptoms

Timeline

• Start date: 2008-05-01
• Primary completion: 2009-02-01
• Completion: 2009-02-01
• First posted: 2008-03-10
• Last updated: 2019-01-02
• Results posted: 2014-11-18